Please sign in so that we can notify you about a reply
Indications/Uses
Ciprofloxacin is indicated for the treatment of the following infections: Susceptible strain: Escherichia coli, Shigella, Salmonella, Citrobacter, Klebsiella, Enterobacter, Serratia spp, Hafnia proteus (Indole positive and negative), Pseudomonas, Neisseria, Acinetobacter, Streptococcus, Chlamydia, Staphylococcus, Corynebacterium, Bacteroides, Clostridium.
Infections: Respiratory infections, ear-nose-laryngopharyngeal infection, oral cavity-tooth-jaw infection, renal or urinary tract infections, genital infections including gonorrhea, gastrointestinal tract infections, biliary secretion, infection and wound of soft tissue, bone and joint infections, gynaecological and obstetric infection, sepsis, meningitis, peritonitis, ophthalmic infections.
Infections: Respiratory infections, ear-nose-laryngopharyngeal infection, oral cavity-tooth-jaw infection, renal or urinary tract infections, genital infections including gonorrhea, gastrointestinal tract infections, biliary secretion, infection and wound of soft tissue, bone and joint infections, gynaecological and obstetric infection, sepsis, meningitis, peritonitis, ophthalmic infections.
Dosage/Direction for Use
Dosage: Usual adult dosage is 100-400mg I.V., every 12 hours.
The recommended adult dosage for urinary tract infections of mild to moderate severity is 200 mg I.V. every 12 hours. For severe or complicated urinary tract infections, the recommended dosage is 400 mg I.V. every 12 hours.
The recommended adult dosage for lower respiratory tract infections, skin and skin structure infections, and bone and joint infections of mild to moderate severity is 400 mg I.V. every 12 hours.
Duration of therapy: Duration of ciprofloxacin injection therapy is usually 7-14 day, for infections of bone and joint it is administered over 4-6 weeks or more. Also, it is administered for 2 more days after symptom is disappeared.
Ciprofloxacin is administered by intravenous injection over 60 minutes. The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative microorganism, the integrity of the patient's host-defense mechanisms and the status of renal and hepatic function. Parenteral therapy may be changed to oral ciprofloxacin when the condition warrants, at the discretion of the physician.
Renal impairment: The following provides dosage guidelines for use in patients with renal impairment; however, monitoring of serum drug levels provides the most reliable basis for dosage adjustment.
Creatinine Clearance (mL/min) >30 mL/min: See usual adult dosage.
Creatinine Clearance (mL/min) 5-29 mL/min: 200-400 mg q 18-24 hr.
The recommended adult dosage for urinary tract infections of mild to moderate severity is 200 mg I.V. every 12 hours. For severe or complicated urinary tract infections, the recommended dosage is 400 mg I.V. every 12 hours.
The recommended adult dosage for lower respiratory tract infections, skin and skin structure infections, and bone and joint infections of mild to moderate severity is 400 mg I.V. every 12 hours.
Duration of therapy: Duration of ciprofloxacin injection therapy is usually 7-14 day, for infections of bone and joint it is administered over 4-6 weeks or more. Also, it is administered for 2 more days after symptom is disappeared.
Ciprofloxacin is administered by intravenous injection over 60 minutes. The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative microorganism, the integrity of the patient's host-defense mechanisms and the status of renal and hepatic function. Parenteral therapy may be changed to oral ciprofloxacin when the condition warrants, at the discretion of the physician.
Renal impairment: The following provides dosage guidelines for use in patients with renal impairment; however, monitoring of serum drug levels provides the most reliable basis for dosage adjustment.
Creatinine Clearance (mL/min) >30 mL/min: See usual adult dosage.
Creatinine Clearance (mL/min) 5-29 mL/min: 200-400 mg q 18-24 hr.
Use In Pregnancy & Lactation
Ciprofloxacin is excreted in human milk. Therefore, a decision should be made to discontinue nursing or to avoid using the drug.
Adverse Reactions
Shock: Rarely shock may occur. Therefore careful observation is required. In the event of symptoms such as dropping of blood pressure, dyspnea and thoracic compression, administration is discontinued and appropriate measures are taken.
Hypersensitivity: In the event of hypersensitivity such as eruption, flare, pruritus, edema, fever, serum sickness-like syndrome, photosensitivity reaction with vesicle or erythema, therapy should be discontinued.
Skin: Rarely petechia, erythema multiforme, erythema nodosum, fixed drug eruption, life threatening mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell syndrome) or fixed eruption may occur. Therefore careful observation is required. In the event of symptoms administration is discontinued.
Urogenital system: Occasionally elevation of BUN and serum creatinine, rarely acute renal failure, renal dysfunction, vaginal candidiasis, hematuria, crystalluria, interstitial nephritis may occur.
Hepatic: Occasionally abnormal hepatic function value (increase of ALT, AST and ALP, bilirubinemia) rarely jaundice, cholestatic jaundice, hepatitis, hepatic necrosis (very rarely progressed to hepatic failure life threatening hepatic failure) may occur. Therefore careful observation is required. In the event of symptoms administration is discontinued and appropriate measures are taken.
Blood: Agranulocytosis, pancytopenia (very rarely life threatening) may occur. Occasionally leukopenia, thrombocytopenia, eosinophilia, rarely leukocytosis, erythrocytopenia, decrease of hemoglobin, decrease of hematocrit value, anemia, granulocytopenia, leukocytolysis, change of prothrombin value, thrombocytopenia, thrombocythemia, hemolytic anemia, petechia or myelosuppression (life threatening) may occur. Therefore careful observation is required. In the event of symptoms administration is discontinued.
Gastrointestinal: Colitis accompanying hemafecia including pseudomembranous colitis (rarely life threatening) may occur. In the event of abdominal pain and frequent diarrhea, administration is discontinued and appropriate measures are taken. Occasionally anorexia, diarrhea, abdominal discomfort, nausea, vomiting, abdominal pain, abdominal distension and rarely stomatitis, oral candidiasis, GI candidiasis or pancreatitis may occur.
Nervous system: Occasionally headache, dizziness, insomnia, agitation, alienation rarely sensory paralysis of tongue, drowsiness, tremolo, visual disturbance, hallucination, sweating, paresthesia (peripheral paraplegia), anxiety, nightmares, depression, tremor, convulsion, hypoesthesia, convulsive seizure, gait disturbance, psychosis, intracranial hypertension, ataxia, hyperesthesia, hypertonia or single twitch may occur. Attack or sleep disorder may occur.
Muscle: Muscle pain, muscular weakness, elevated CPK, rhabdomyolysis accompanying aggravation of renal function with elevation of myoglobin in urine or blood may occur. Therefore careful administration is required. Occasionally joint pain, rarely arthredema, myasthenia, tenontitis (Achilles tenontitis), tendon rupture (Achilles tendon rupture) may occur. Severe myasthenia may be aggravated.
Respiratory: Interstitial pneumonia accompanying with fever, cough, dyspnea disorder of chest X-ray, eosinophilia may occur. In occurrences of these symptoms, appropriate treatment including adrenocorticosteroid are taken.
Body as a whole: Occasionally candidiasis, anergia (weakness fatigue), rarely pain, melalgia, back pain, chest pain or joint pain may occur.
Sensory: Occasionally dysgeusia, rarely tinnitus, transient hearing loss, visual disturbance, double vision, chromatopsia, dysgeusia, olfactory disorders, anosmia (reversibly after drug discontinuation).
Metabolism disorder: Rarely edema (peripheral, vessel, facial, Pharyngeal), hyperglycemia, increase of amylase. Increase of lipase may occur. Hypoglycemia has rarely reported in other new quinolone antibiotics (elderly person, particularly with renal failure).
Cardiovascular system: Occasionally (thrombotic) phlebitis, rarely frequent pulse, migraine, syncope, angiectasia (flushing), hypotension, vasculitis, petechia, bleeding blister, acne, crust formation may occur.
Local I.V. site reactions have been reported with the intravenous administration of ciprofloxacin. These reactions are more frequent if the infusion time is 30 minutes or less. These may appear as local skin reactions which resolve rapidly upon completion of the infusion. Subsequent intravenous administration is not contraindicated unless the reactions recur or worsen.
Hypersensitivity: In the event of hypersensitivity such as eruption, flare, pruritus, edema, fever, serum sickness-like syndrome, photosensitivity reaction with vesicle or erythema, therapy should be discontinued.
Skin: Rarely petechia, erythema multiforme, erythema nodosum, fixed drug eruption, life threatening mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell syndrome) or fixed eruption may occur. Therefore careful observation is required. In the event of symptoms administration is discontinued.
Urogenital system: Occasionally elevation of BUN and serum creatinine, rarely acute renal failure, renal dysfunction, vaginal candidiasis, hematuria, crystalluria, interstitial nephritis may occur.
Hepatic: Occasionally abnormal hepatic function value (increase of ALT, AST and ALP, bilirubinemia) rarely jaundice, cholestatic jaundice, hepatitis, hepatic necrosis (very rarely progressed to hepatic failure life threatening hepatic failure) may occur. Therefore careful observation is required. In the event of symptoms administration is discontinued and appropriate measures are taken.
Blood: Agranulocytosis, pancytopenia (very rarely life threatening) may occur. Occasionally leukopenia, thrombocytopenia, eosinophilia, rarely leukocytosis, erythrocytopenia, decrease of hemoglobin, decrease of hematocrit value, anemia, granulocytopenia, leukocytolysis, change of prothrombin value, thrombocytopenia, thrombocythemia, hemolytic anemia, petechia or myelosuppression (life threatening) may occur. Therefore careful observation is required. In the event of symptoms administration is discontinued.
Gastrointestinal: Colitis accompanying hemafecia including pseudomembranous colitis (rarely life threatening) may occur. In the event of abdominal pain and frequent diarrhea, administration is discontinued and appropriate measures are taken. Occasionally anorexia, diarrhea, abdominal discomfort, nausea, vomiting, abdominal pain, abdominal distension and rarely stomatitis, oral candidiasis, GI candidiasis or pancreatitis may occur.
Nervous system: Occasionally headache, dizziness, insomnia, agitation, alienation rarely sensory paralysis of tongue, drowsiness, tremolo, visual disturbance, hallucination, sweating, paresthesia (peripheral paraplegia), anxiety, nightmares, depression, tremor, convulsion, hypoesthesia, convulsive seizure, gait disturbance, psychosis, intracranial hypertension, ataxia, hyperesthesia, hypertonia or single twitch may occur. Attack or sleep disorder may occur.
Muscle: Muscle pain, muscular weakness, elevated CPK, rhabdomyolysis accompanying aggravation of renal function with elevation of myoglobin in urine or blood may occur. Therefore careful administration is required. Occasionally joint pain, rarely arthredema, myasthenia, tenontitis (Achilles tenontitis), tendon rupture (Achilles tendon rupture) may occur. Severe myasthenia may be aggravated.
Respiratory: Interstitial pneumonia accompanying with fever, cough, dyspnea disorder of chest X-ray, eosinophilia may occur. In occurrences of these symptoms, appropriate treatment including adrenocorticosteroid are taken.
Body as a whole: Occasionally candidiasis, anergia (weakness fatigue), rarely pain, melalgia, back pain, chest pain or joint pain may occur.
Sensory: Occasionally dysgeusia, rarely tinnitus, transient hearing loss, visual disturbance, double vision, chromatopsia, dysgeusia, olfactory disorders, anosmia (reversibly after drug discontinuation).
Metabolism disorder: Rarely edema (peripheral, vessel, facial, Pharyngeal), hyperglycemia, increase of amylase. Increase of lipase may occur. Hypoglycemia has rarely reported in other new quinolone antibiotics (elderly person, particularly with renal failure).
Cardiovascular system: Occasionally (thrombotic) phlebitis, rarely frequent pulse, migraine, syncope, angiectasia (flushing), hypotension, vasculitis, petechia, bleeding blister, acne, crust formation may occur.
Local I.V. site reactions have been reported with the intravenous administration of ciprofloxacin. These reactions are more frequent if the infusion time is 30 minutes or less. These may appear as local skin reactions which resolve rapidly upon completion of the infusion. Subsequent intravenous administration is not contraindicated unless the reactions recur or worsen.
Storage
Store at temperatures not exceeding 30°C.
Action
Antibacterial.
MedsGo Class
Quinolones
Features
Dosage
500 mg
Ingredients
- Ciprofloxacin
Packaging
Tablet 100's
Generic Name
Ciprofloxacin Hydrochloride
Registration Number
DRP-7100
Classification
Prescription Drug (RX)
Product Questions
Questions
